The AMF13 trial has now been activated at LINEAR research institute

As a type of immunotherapy, AFM13 does not kill cancer cells directly but encourages the body’s own immune system to seek out and destroy the cells. It works by activating a type of immune cell, called a natural killer (NK) cell, and directing them to destroy the cancerous cells which harbour CD30, a molecule seen commonly on T-cell lymphoma cancer cells.

When the natural killer cell is linked to the cancerous cell by AFM13 binding, its cell-killing ability is activated. This results in the body’s own immune cells destroying the cancer in a targeted manner.

For further details on the trial, visit our Trials page on our website: